跳到正文
原文
MedTech Dive 器械媒体· Nick Paul Taylor·· 15 天前AI 评分28

MiniMed任命David Segal为首席医疗官

MiniMed names David Segal chief medical officer

AI 导读

MiniMed宣布David Segal接替Robert Vigersky担任首席医疗官,Segal拥有超过20年儿科内分泌学、数字健康和医疗创新经验,将利用技术改善糖尿病患者的临床结果。Segal表示,他期待将技术应用于减少糖尿病管理负担并提高患者结果。

正文

An article from site logo

Dive Brief

Segal is succeeding Robert Vigersky, who is transitioning to a chief medical officer emeritus role ahead of his planned retirement at the end of next year.

Published Nov. 5, 2026

By

A person sits at a table with food, wearing a pink, rectangular device attached to a striped dress.

The MiniMed Flex insulin pump. Courtesy of MiniMed

A headshot of a person wearing a blue suit with a white shirt and blue tie, standing in front of a white background

David Segal, MiniMed's chief medical officer

Courtesy of MiniMed

Name: David Segal

New title: Chief medical officer, MiniMed

Previous title: Medical director of innovation and remote monitoring care, Parkview Health’s Mirro Center for Research and Innovation

MiniMed said Tuesday it has appointed Dr. David Segal to succeed Robert Vigersky as chief medical officer.

Joining MiniMed, a Medtronic spinout, positions Segal to use technology to improve clinical outcomes in diabetes. Segal landed the job on the strength of a resume that includes more than 20 years of experience in pediatric endocrinology, digital health and healthcare innovation. At Parkview Health’s Mirro Center for Research and Innovation, Segal helped create a pediatric endocrinology service. 

Segal also set up South Africa’s largest diabetes and endocrinology practice and co-founded Guidepost, a digital health company.

“I’ve spent much of my career looking at how we can use technology and data to make diabetes care more proactive, personalized and accessible,” Segal said in a statement. “What excites me about MiniMed is the opportunity to bring that thinking into the development of technologies that can reduce the daily burden of managing diabetes and help more people achieve better outcomes.”

Vigersky will transition to the role of chief medical officer emeritus ahead of his planned retirement at the end of next year. Having joined the Medtronic Diabetes business in 2015, Vigersky rose to the position of CMO in 2019 and helped advance the company’s clinical strategy.

Segal joined MiniMed following a quarter in which sales grew 17% to $843 million. MiniMed raised its organic revenue growth guidance for fiscal 2027 based on the first-quarter earnings. The diabetes company attributed its first-quarter growth to developments including the launch of its Instinct sensor, which is made by Abbott.

MiniMed recently completed its separation from Medtronic.

来源:MedTech Dive 器械媒体 · medtechdive.com